SK19072001A3 - Anti-alfa'v'beta'3' rekombinantné ľudské protilátky, nukleové kyseliny ich kódujúce a spôsoby použitia - Google Patents

Anti-alfa'v'beta'3' rekombinantné ľudské protilátky, nukleové kyseliny ich kódujúce a spôsoby použitia Download PDF

Info

Publication number: SK19072001A3
Authority: SK; Slovakia
Prior art keywords: seq; antibody; implanted; enhanced; region
Prior art date: 1999-06-24

Application number

SK1907-2001A

Other languages

English (en)

Slovak (sk)

Inventor

William D. Huse

Herren Wu

Original Assignee

Applied Molecular Evolution, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-24

Filing date

2000-06-23

Publication date

2002-07-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23331188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK19072001(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-23 Application filed by Applied Molecular Evolution, Inc. filed Critical Applied Molecular Evolution, Inc.

2002-07-02 Publication of SK19072001A3 publication Critical patent/SK19072001A3/sk

Links

150000007523 nucleic acids Chemical class 0.000 title claims abstract description 116
108020004707 nucleic acids Proteins 0.000 title claims abstract description 106
102000039446 nucleic acids Human genes 0.000 title claims abstract description 106
238000000034 method Methods 0.000 title claims abstract description 87
230000027455 binding Effects 0.000 claims abstract description 171
239000012634 fragment Substances 0.000 claims abstract description 128
230000002401 inhibitory effect Effects 0.000 claims abstract description 33
125000003729 nucleotide group Chemical group 0.000 claims description 103
239000002773 nucleotide Substances 0.000 claims description 99
108010047041 Complementarity Determining Regions Proteins 0.000 claims description 89
108091028043 Nucleic acid sequence Proteins 0.000 claims description 36
230000001747 exhibiting effect Effects 0.000 abstract description 2
125000003275 alpha amino acid group Chemical group 0.000 description 107
108090000765 processed proteins & peptides Proteins 0.000 description 100
102000004196 processed proteins & peptides Human genes 0.000 description 96
229920001184 polypeptide Polymers 0.000 description 95
150000001413 amino acids Chemical class 0.000 description 66
238000006467 substitution reaction Methods 0.000 description 66
102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 59
101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 59
108010044426 integrins Proteins 0.000 description 56
102000006495 integrins Human genes 0.000 description 56
230000035772 mutation Effects 0.000 description 55
125000000539 amino acid group Chemical group 0.000 description 47
210000004027 cell Anatomy 0.000 description 46
230000005764 inhibitory process Effects 0.000 description 44
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 43
206010028980 Neoplasm Diseases 0.000 description 42
230000000694 effects Effects 0.000 description 42
201000010099 disease Diseases 0.000 description 38
108091034117 Oligonucleotide Proteins 0.000 description 34
108010049003 Fibrinogen Proteins 0.000 description 29
102000008946 Fibrinogen Human genes 0.000 description 29
229940012952 fibrinogen Drugs 0.000 description 29
230000006870 function Effects 0.000 description 29
238000002703 mutagenesis Methods 0.000 description 28
231100000350 mutagenesis Toxicity 0.000 description 28
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 26
108090000623 proteins and genes Proteins 0.000 description 22
238000012216 screening Methods 0.000 description 22
238000002965 ELISA Methods 0.000 description 21
108020004705 Codon Proteins 0.000 description 19
241001529936 Murinae Species 0.000 description 19
206010029113 Neovascularisation Diseases 0.000 description 19
230000004048 modification Effects 0.000 description 19
238000012986 modification Methods 0.000 description 19
230000001965 increasing effect Effects 0.000 description 18
230000021164 cell adhesion Effects 0.000 description 16
239000007787 solid Substances 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
230000000875 corresponding effect Effects 0.000 description 15
230000001575 pathological effect Effects 0.000 description 15
238000009396 hybridization Methods 0.000 description 14
238000002513 implantation Methods 0.000 description 14
238000003752 polymerase chain reaction Methods 0.000 description 14
230000004614 tumor growth Effects 0.000 description 14
239000013598 vector Substances 0.000 description 14
102000002260 Alkaline Phosphatase Human genes 0.000 description 13
108020004774 Alkaline Phosphatase Proteins 0.000 description 13
102100035140 Vitronectin Human genes 0.000 description 13
108010031318 Vitronectin Proteins 0.000 description 13
230000033115 angiogenesis Effects 0.000 description 13
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
239000000047 product Substances 0.000 description 12
239000000203 mixture Substances 0.000 description 11
241000588724 Escherichia coli Species 0.000 description 10
241000283973 Oryctolagus cuniculus Species 0.000 description 10
238000013459 approach Methods 0.000 description 10
238000010276 construction Methods 0.000 description 10
238000010494 dissociation reaction Methods 0.000 description 10
230000005593 dissociations Effects 0.000 description 10
230000001404 mediated effect Effects 0.000 description 10
238000002515 oligonucleotide synthesis Methods 0.000 description 10
241000283707 Capra Species 0.000 description 9
230000000295 complement effect Effects 0.000 description 9
239000003446 ligand Substances 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
238000010367 cloning Methods 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
230000008859 change Effects 0.000 description 7
239000003814 drug Substances 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
230000000717 retained effect Effects 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
201000009030 Carcinoma Diseases 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
238000011161 development Methods 0.000 description 6
210000002889 endothelial cell Anatomy 0.000 description 6
230000005714 functional activity Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
201000001441 melanoma Diseases 0.000 description 6
230000008569 process Effects 0.000 description 6
230000017854 proteolysis Effects 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000012148 binding buffer Substances 0.000 description 5
238000012512 characterization method Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000006957 competitive inhibition Effects 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
230000012010 growth Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
238000005259 measurement Methods 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
208000037803 restenosis Diseases 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
-1 thromspondin Proteins 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
101150111020 GLUL gene Proteins 0.000 description 4
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
102000004264 Osteopontin Human genes 0.000 description 4
108010081689 Osteopontin Proteins 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
238000002955 isolation Methods 0.000 description 4
238000013508 migration Methods 0.000 description 4
239000013642 negative control Substances 0.000 description 4
238000005457 optimization Methods 0.000 description 4
230000007170 pathology Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
101710171221 30S ribosomal protein S11 Proteins 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
108091092195 Intron Proteins 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 3
208000001132 Osteoporosis Diseases 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
102000019997 adhesion receptor Human genes 0.000 description 3
108010013985 adhesion receptor Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000012292 cell migration Effects 0.000 description 3
230000009137 competitive binding Effects 0.000 description 3
230000010595 endothelial cell migration Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000005745 host immune response Effects 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
239000003550 marker Substances 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
125000003003 spiro group Chemical group 0.000 description 3
238000004448 titration Methods 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
238000005406 washing Methods 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 description 2
241000024188 Andala Species 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
241001524679 Escherichia virus M13 Species 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
102000016359 Fibronectins Human genes 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
102100022337 Integrin alpha-V Human genes 0.000 description 2
SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 2
108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
208000028990 Skin injury Diseases 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000009824 affinity maturation Effects 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000002491 angiogenic effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000037029 cross reaction Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
210000001322 periplasm Anatomy 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
230000007505 plaque formation Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000008439 repair process Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
108010047303 von Willebrand Factor Proteins 0.000 description 2
102100036537 von Willebrand factor Human genes 0.000 description 2
229960001134 von willebrand factor Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
YCZTUBHUGXHSKE-VVCAKUBGSA-N 1-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 YCZTUBHUGXHSKE-VVCAKUBGSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
QWTBDIBOOIAZEF-UHFFFAOYSA-N 3-[chloro-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile Chemical compound CC(C)N(C(C)C)P(Cl)OCCC#N QWTBDIBOOIAZEF-UHFFFAOYSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000310247 Amyna axis Species 0.000 description 1
208000003120 Angiofibroma Diseases 0.000 description 1
VHUKCUHLFMRHOD-MELADBBJSA-N Asp-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O VHUKCUHLFMRHOD-MELADBBJSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
101100058944 Gallus gallus CALM gene Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
FAQVCWVVIYYWRR-WHFBIAKZSA-N Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
101000803709 Homo sapiens Vitronectin Proteins 0.000 description 1
TWVKGYNQQAUNRN-ACZMJKKPSA-N Ile-Ser Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O TWVKGYNQQAUNRN-ACZMJKKPSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
101150044775 LYS1 gene Proteins 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
NOFBJKKOPKJDCO-KKXDTOCCSA-N Phe-Ala-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NOFBJKKOPKJDCO-KKXDTOCCSA-N 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
208000012641 Pigmentation disease Diseases 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
101000838407 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Protein TBF1 Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
239000007984 Tris EDTA buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
101100497923 Viola odorata Voc1 gene Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
108010048673 Vitronectin Receptors Proteins 0.000 description 1
101100323865 Xenopus laevis arg1 gene Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000012491 analyte Substances 0.000 description 1
229940125644 antibody drug Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000002742 combinatorial mutagenesis Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000003235 crystal violet staining Methods 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000037313 granulation tissue formation Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000054751 human RUNX1T1 Human genes 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
201000005264 laryngeal carcinoma Diseases 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000010232 migration assay Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
150000004995 p-toluidines Chemical class 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000008263 repair mechanism Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
239000004149 tartrazine Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
238000000954 titration curve Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1907-2001A 1999-06-24 2000-06-23 Anti-alfa'v'beta'3' rekombinantné ľudské protilátky, nukleové kyseliny ich kódujúce a spôsoby použitia SK19072001A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/339,922 US6531580B1 (en)	1999-06-24	1999-06-24	Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
PCT/US2000/017454 WO2000078815A1 (en)	1999-06-24	2000-06-23	ANTI-αvβ3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE

Publications (1)

Publication Number	Publication Date
SK19072001A3 true SK19072001A3 (sk)	2002-07-02

Family

ID=23331188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1907-2001A SK19072001A3 (sk)	1999-06-24	2000-06-23	Anti-alfa'v'beta'3' rekombinantné ľudské protilátky, nukleové kyseliny ich kódujúce a spôsoby použitia

Country Status (19)

Country	Link
US (3)	US6531580B1 (xx)
EP (1)	EP1189946A1 (xx)
JP (2)	JP4521802B2 (xx)
KR (1)	KR100928748B1 (xx)
AU (3)	AU781501C (xx)
BR (1)	BR0011849A (xx)
CA (1)	CA2375236A1 (xx)
CR (1)	CR6538A (xx)
CZ (1)	CZ302177B6 (xx)
HU (1)	HUP0201783A3 (xx)
IL (2)	IL147145A0 (xx)
MX (1)	MXPA01013362A (xx)
NO (1)	NO20016243L (xx)
NZ (3)	NZ523291A (xx)
PL (1)	PL352251A1 (xx)
SK (1)	SK19072001A3 (xx)
TR (1)	TR200103703T2 (xx)
WO (1)	WO2000078815A1 (xx)
ZA (1)	ZA200110161B (xx)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6590079B2 (en) *	1997-01-30	2003-07-08	Ixsys, Incorporated	Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6596850B1 (en) *	1998-01-30	2003-07-22	Ixsys, Incorporated	Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6531580B1 (en) *	1999-06-24	2003-03-11	Ixsys, Inc.	Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
EP2295580A1 (en) *	2000-04-17	2011-03-16	Dyax Corp.	Methods of constructing display libraries of genetic packages for members of a diverse family of peptides
US8288322B2 (en)	2000-04-17	2012-10-16	Dyax Corp.	Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE60143544D1 (de)	2000-12-12	2011-01-05	Medimmune Llc	Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
CA2432377C (en)	2000-12-18	2012-10-09	Dyax Corp.	Focused libraries of genetic packages
WO2002070007A1 (en) *	2001-03-02	2002-09-12	Medimmune, Inc.	Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
US7390885B2 (en)	2001-11-26	2008-06-24	Cell Matrix, Inc.	Humanized collagen antibodies and related methods
US7365167B2 (en)	2001-11-26	2008-04-29	Cell Matrix, Inc.	Humanized collagen antibodies and related methods
WO2003075957A1 (en) *	2002-03-04	2003-09-18	Medimmune, Inc.	The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
JP2005525368A (ja) *	2002-03-04	2005-08-25	メディミューン，インコーポレーテッド	インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
AU2005254062B2 (en) *	2002-04-11	2011-02-17	Medimmune, Llc	High pressure spray-dry of bioactive materials
US20040067532A1 (en) *	2002-08-12	2004-04-08	Genetastix Corporation	High throughput generation and affinity maturation of humanized antibody
JP2006516957A (ja) *	2002-11-15	2006-07-13	セントカー・インコーポレーテツド	Ｉｌ−６アンタゴニストの抗血管形成用途
US20040208869A1 (en) *	2003-01-30	2004-10-21	Medimmune, Inc.	Uses of anti-integrin alphanubeta3 antibody formulations
US20040208870A1 (en) *	2003-01-30	2004-10-21	Medimmune, Inc.	Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
US20060234296A1 (en) *	2003-02-01	2006-10-19	Sanjaya Singh	Method for generating high affinity antibodies
WO2004091510A2 (en)	2003-04-11	2004-10-28	Medimmune, Inc.	Recombinant il-9 antibodies and uses thereof
US9708410B2 (en)	2003-05-30	2017-07-18	Janssen Biotech, Inc.	Anti-tissue factor antibodies and compositions
US8668926B1 (en)	2003-09-15	2014-03-11	Shaker A. Mousa	Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8071134B2 (en)	2003-09-15	2011-12-06	Ordway Research Institute, Inc.	Thyroid hormone analogs and methods of use
WO2005027895A2 (en)	2003-09-15	2005-03-31	Ordway Research Institute	Thyroid hormone analogs and methods of use in angiogenesis
US9198887B2 (en)	2003-09-15	2015-12-01	Nanopharmaceuticals Llc	Thyroid hormone analogs and methods of use
JPWO2005068504A1 (ja) *	2004-01-19	2008-01-10	株式会社医学生物学研究所	炎症性サイトカイン抑制剤
US7271245B2 (en) *	2004-02-13	2007-09-18	The Scripps Research Institute	Methods and compositions for inhibition of metastasis
US7691379B2 (en)	2004-04-12	2010-04-06	Medimmune, Llc	Anti-IL-9 antibody formulations
US7351739B2 (en)	2004-04-30	2008-04-01	Wellgen, Inc.	Bioactive compounds and methods of uses thereof
US8187595B2 (en)	2004-05-07	2012-05-29	The University Of North Carolina At Chapel Hill	Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
ATE461708T1 (de)	2004-05-07	2010-04-15	Univ North Carolina	Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
WO2006012415A2 (en)	2004-07-20	2006-02-02	Critical Therapeutics, Inc.	Rage protein derivatives
JP2008510007A (ja) *	2004-08-16	2008-04-03	メディミューン，インコーポレーテッド	抗体依存性細胞性細胞傷害活性が増強されたＥｐｈ受容体Ｆｃ変異体
CN101102758B (zh)	2004-09-15	2011-11-16	奥德威研究院	促进血管新生的甲状腺激素类似物
EP1809326A4 (en)	2004-10-27	2009-11-04	Medimmune Inc	MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN
EP1819732A2 (en)	2004-12-06	2007-08-22	Kirin Beer Kabushiki Kaisha	Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2006138429A2 (en)	2005-06-16	2006-12-28	The Feinstein Institute For Medical Research	Antibodies against hmgb1 and fragments thereof
JP2008546805A (ja)	2005-06-23	2008-12-25	メディミューン，エルエルシー	最適な凝集および断片化プロフィールを有する抗体製剤
US10130686B2 (en)	2005-09-15	2018-11-20	Nanopharmaceuticals Llc	Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en)	2005-09-15	2016-11-22	Nanopharmaceuticals Llc	Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
WO2007035612A2 (en)	2005-09-16	2007-03-29	Ordway Research Institute, Inc.	Polyphenol conjugates as rgd-binding compounds and methods of use
AU2007272970C1 (en)	2006-07-11	2013-01-10	Roy C. Levitt	Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA2660519A1 (en)	2006-08-10	2008-02-21	Roy C. Levitt	Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
JP2010506842A (ja)	2006-10-16	2010-03-04	メディミューン，エルエルシー	半減期が短縮された分子、その組成物および使用
WO2008140507A2 (en)	2006-12-22	2008-11-20	Clf Medical Technology Acceleration Program, Inc.	Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US8877688B2 (en)	2007-09-14	2014-11-04	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
DK3124497T3 (da) *	2007-09-14	2020-05-11	Adimab Llc	Rationelt designede syntetiske antistofbiblioteker og anvendelser deraf
WO2009114815A1 (en)	2008-03-13	2009-09-17	Dyax Corp	Libraries of genetic packages comprising novel hc cdr3 designs
CA2968164C (en)	2008-04-24	2019-08-20	Dyax Corp.	Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
MX2010011955A (es)	2008-04-29	2011-01-21	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
CN102112494A (zh)	2008-06-03	2011-06-29	雅培制药有限公司	双重可变结构域免疫球蛋白及其用途
SG191639A1 (en)	2008-06-03	2013-07-31	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
NZ589795A (en)	2008-06-16	2013-02-22	Patrys Ltd	Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
RU2011104348A (ru)	2008-07-08	2012-08-20	Эбботт Лэборетриз (Us)	Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
WO2010120506A1 (en)	2009-03-31	2010-10-21	Ordway Research Institute, Inc.	Combination treatment of cancer with cetuximab and tetrac
ES2548030T3 (es)	2009-06-01	2015-10-13	Medimmune, Llc	Moléculas con semividas prolongadas y usos de las mismas
WO2010148007A2 (en)	2009-06-17	2010-12-23	Ordway Research Institute, Inc.	Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
AU2010291902A1 (en) *	2009-09-14	2012-04-05	Dyax Corp.	Libraries of genetic packages comprising novel HC CDR3 designs
EP2488658A4 (en)	2009-10-15	2013-06-19	Abbvie Inc	IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
KR102810907B1 (ko)	2010-07-16	2025-05-21	아디맵 엘엘씨	항체 라이브러리
MX341579B (es)	2010-08-03	2016-08-25	Abbvie Inc *	Inmunoglobulinas de dominio variable doble y usos de las mismas.
BR112013004581A2 (pt)	2010-08-26	2017-06-27	Abbvie Inc	imunoglobulinas de domínio variável dual e seus usos
US8802240B2 (en)	2011-01-06	2014-08-12	Nanopharmaceuticals Llc	Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
WO2013098419A1 (en)	2011-12-28	2013-07-04	Immunoqure Ag	Method of providing monoclonal auto-antibodies with desired specificity
UY34558A (es)	2011-12-30	2013-07-31	Abbvie Inc	Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
US9073996B2 (en)	2012-08-31	2015-07-07	The University Of North Carolina At Chapel Hill	Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
MY194330A (en)	2012-11-01	2022-11-28	Abbvie Inc	Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
BR112015023797A2 (pt)	2013-03-15	2017-10-24	Abbvie Inc	proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
CA2917112C (en)	2013-07-03	2022-07-05	Immunoqure Ag	Human anti-ifn-alpha antibodies
FR3024049A1 (fr)	2014-07-28	2016-01-29	Total Raffinage Chimie	Dispositif de terminaison d'un reacteur d'une unite de craquage catalytique fluide
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2017279536A1 (en)	2016-06-07	2018-12-20	Nanopharmaceuticals, Llc	Non-cleavable polymer conjugated with αvβ3 integrin thyroid antagonists
US11351137B2 (en)	2018-04-11	2022-06-07	Nanopharmaceuticals Llc	Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en)	2018-04-11	2019-06-25	Nanopharmaceuticals, Llc.	Composition and method for dual targeting in treatment of neuroendocrine tumors
US10961204B1 (en)	2020-04-29	2021-03-30	Nanopharmaceuticals Llc	Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en)	2021-12-09	2023-08-15	Nanopharmaceuticals Llc	Polymer conjugated thyrointegrin antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5264563A (en)	1990-08-24	1993-11-23	Ixsys Inc.	Process for synthesizing oligonucleotides with random codons
US5579230A (en) *	1991-06-10	1996-11-26	General Motors Corporation	Vehicle speed estimation for antilock braking using a chassis accelerometer
US5667988A (en) *	1992-01-27	1997-09-16	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2132091C (en)	1992-04-03	2008-09-16	Kyung J. Kim	Antibodies to alphavbeta3 integrin
IT1268004B1 (it) *	1994-02-02	1997-02-20	Giuseppe Lambertini	Dispositivo per il bloccaggio di un pezzo su un piano d'appoggio, quale una tavola di macchina operatrice.
US5753230A (en)	1994-03-18	1998-05-19	The Scripps Research Institute	Methods and compositions useful for inhibition of angiogenesis
WO1996040250A2 (en)	1995-06-07	1996-12-19	Centocor, Inc.	Platelet-specific chimeric immunoglobulin and methods of use therefor
US6596850B1 (en)	1998-01-30	2003-07-22	Ixsys, Incorporated	Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6590079B2 (en)	1997-01-30	2003-07-08	Ixsys, Incorporated	Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6531580B1 (en) *	1999-06-24	2003-03-11	Ixsys, Inc.	Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same

1999
- 1999-06-24 US US09/339,922 patent/US6531580B1/en not_active Expired - Lifetime
2000
- 2000-06-23 CA CA002375236A patent/CA2375236A1/en not_active Abandoned
- 2000-06-23 NZ NZ523291A patent/NZ523291A/en not_active IP Right Cessation
- 2000-06-23 SK SK1907-2001A patent/SK19072001A3/sk not_active Application Discontinuation
- 2000-06-23 NZ NZ516251A patent/NZ516251A/xx not_active IP Right Cessation
- 2000-06-23 JP JP2001505572A patent/JP4521802B2/ja not_active Expired - Fee Related
- 2000-06-23 AU AU56374/00A patent/AU781501C/en not_active Ceased
- 2000-06-23 WO PCT/US2000/017454 patent/WO2000078815A1/en active Application Filing
- 2000-06-23 CZ CZ20014655A patent/CZ302177B6/cs not_active IP Right Cessation
- 2000-06-23 NZ NZ533727A patent/NZ533727A/en not_active IP Right Cessation
- 2000-06-23 BR BR0011849-4A patent/BR0011849A/pt not_active Application Discontinuation
- 2000-06-23 PL PL00352251A patent/PL352251A1/xx not_active IP Right Cessation
- 2000-06-23 HU HU0201783A patent/HUP0201783A3/hu unknown
- 2000-06-23 KR KR1020017016479A patent/KR100928748B1/ko not_active Expired - Fee Related
- 2000-06-23 EP EP00941707A patent/EP1189946A1/en not_active Withdrawn
- 2000-06-23 TR TR2001/03703T patent/TR200103703T2/xx unknown
- 2000-06-23 IL IL14714500A patent/IL147145A0/xx not_active IP Right Cessation
- 2000-06-23 MX MXPA01013362A patent/MXPA01013362A/es active IP Right Grant
2001
- 2001-12-11 ZA ZA200110161A patent/ZA200110161B/xx unknown
- 2001-12-19 NO NO20016243A patent/NO20016243L/no unknown
- 2001-12-20 CR CR6538A patent/CR6538A/es not_active Application Discontinuation
2002
- 2002-11-25 US US10/305,231 patent/US7371382B2/en not_active Expired - Fee Related
2005
- 2005-08-25 AU AU2005204251A patent/AU2005204251B2/en not_active Ceased
2008
- 2008-04-14 US US12/102,818 patent/US7667007B2/en not_active Expired - Fee Related
- 2008-12-02 IL IL195649A patent/IL195649A0/en unknown
- 2008-12-19 AU AU2008261144A patent/AU2008261144A1/en not_active Abandoned
2009
- 2009-05-01 JP JP2009111752A patent/JP2009219495A/ja active Pending

Also Published As

Publication number	Publication date
NO20016243L (no)	2002-02-15
NO20016243D0 (no)	2001-12-19
PL352251A1 (en)	2003-08-11
AU2005204251B2 (en)	2008-10-02
IL195649A0 (en)	2009-09-01
JP2009219495A (ja)	2009-10-01
IL147145A0 (en)	2002-08-14
TR200103703T2 (tr)	2002-04-22
JP2004537957A (ja)	2004-12-24
EP1189946A1 (en)	2002-03-27
US6531580B1 (en)	2003-03-11
US20030166872A1 (en)	2003-09-04
AU2008261144A1 (en)	2009-01-22
AU2005204251A1 (en)	2005-09-22
HUP0201783A3 (en)	2011-03-28
NZ533727A (en)	2008-03-28
NZ523291A (en)	2004-09-24
AU5637400A (en)	2001-01-09
CZ20014655A3 (cs)	2002-05-15
CZ302177B6 (cs)	2010-12-01
KR20020034094A (ko)	2002-05-08
AU781501B2 (en)	2005-05-26
CA2375236A1 (en)	2000-12-28
ZA200110161B (en)	2002-09-30
JP4521802B2 (ja)	2010-08-11
HUP0201783A2 (en)	2002-08-28
NZ516251A (en)	2003-03-28
US7667007B2 (en)	2010-02-23
WO2000078815A1 (en)	2000-12-28
AU2005204251A9 (en)	2005-09-22
US7371382B2 (en)	2008-05-13
BR0011849A (pt)	2003-05-27
US20090023900A1 (en)	2009-01-22
KR100928748B1 (ko)	2009-11-25
CR6538A (es)	2006-02-06
AU781501C (en)	2006-04-06
MXPA01013362A (es)	2003-09-04

Publication	Publication Date	Title
KR100928748B1 (ko)	2009-11-25	항-αｖβ3 재조합 인간 항체, 이를 코딩하는 핵산 및사용 방법
AU737569B2 (en)	2001-08-23	Anti-alphav-beta3 recombinant human antibodies, nucleic acids encoding same and methods of use
US20060204492A1 (en)	2006-09-14	Compositions and methods for producing enhanced antibodies
US7504102B2 (en)	2009-03-17	Anti-αvβ3 humanized monoclonal antibodies
WO1998040488A9 (en)	1999-02-25	Anti-alphabeta3 humanized monoclonal antibodies
US20010011125A1 (en)	2001-08-02	Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use

Legal Events

Date	Code	Title	Description
2011-11-04	FC9A	Refused patent application